

COVID-19 outcomes associated with clinical and demographic characteristics in patients hospitalized with severe and critical disease in Peshawar

Muhammad Imran¹, Azharuddin¹, Muhammad Yousaf², Sajjad Khan³, Abdul Jalil Khan⁴, Zafar Iqbal^{1*}, RahmanUllah Jan², Shahid Khan⁵ Muhammad Salman Khan⁶

¹MTI, Lady Reading Hospital, Peshawar, Pakistan

²COVID-19 Hospital, Nishterabad, Peshawar, Pakistan

³Indiana University (IU) School of Public Health, IU, Bloomington, USA

⁴Khyber Medical University, Peshawar, Pakistan

⁵Health Sector Reforms Unit, Health Secretariat, Peshawar, Pakistan

⁶Northwest General Hospital and Research Center, Peshawar, Pakistan

Short title: COVID-19 outcomes associated with clinical and demographic characteristics

***Corresponding Author**

Dr Zafar Iqbal (MBBS, FCPS)

Assistant Professor, Pulmonology

Lady Reading Hospital, Peshawar

25000, Pakistan.

E-mail: drzafariqbalpulmo@gmail.com (ZI)

Abstract

Background: As a novel disease, understanding the relationship between the clinical and demographic characteristics of coronavirus disease 2019 (COVID-19) patients and their outcome is critical. We investigated this relationship in hospitalized patients in a tertiary healthcare setting.

Aims/objectives: To study COVID-19 severity and outcomes in relation to clinical and demographic characteristics of in admitted patients

Methodology: In this cross-sectional study, medical records for 1087 COVID-19 patients were reviewed to extract symptoms, comorbidities, demographic characteristics, and outcomes data. Statistical analyses included the post-stratification chi-square test, independent sample t-test, multivariate logistic regression, and time-to-event analysis.

Results: The majority of the study participants were >50 years old (67%) and male (59%) and had the following symptoms: fever (96%), cough (95%), shortness of breath (73%), loss of taste (77%), and loss of smell (77%). Regarding worst outcome, multivariate regression analysis showed that these characteristics were statistically significant: shortness of breath (adjusted odds ratio [aOR] 31.3; 95% CI, 11.87–82.53; $p < 0.001$), intensive care unit (ICU) admission (aOR 28.3; 95% CI, 9.0–89.6; $p < 0.001$), diabetes mellitus (aOR 5.1; 95% CI, 3.2–8.2; $p < 0.001$), ischemic heart disease (aOR 3.4; 95% CI, 1.6–7; $p = 0.001$), nausea and vomiting (aOR 3.3; 95% CI, 1.7–6.6; $p = 0.001$), and prolonged hospital stay (aOR 1.04; 95% CI, 1.02–1.08; $p = 0.001$), while patients with rhinorrhea were significantly protected (aOR 0.3; 95% CI, 0.2–0.5; $p <$

0.001). A Kaplan–Meier curve showed that the symptoms of shortness of breath, ICU admission, fever, nausea and vomiting, and diarrhea increased the risk of mortality.

Conclusion: Increasing age, certain comorbidities and symptoms, and direct admission to the ICU increased the risk of worse outcomes. Further research is needed to determine risk factors that may increase disease severity and devise a proper risk-scoring system to initiate timely management.

Keywords: COVID-19, SARS-CoV-2, clinico-demographic characteristics, mortality, outcomes

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), a member of the coronavirus family that was responsible for the 2003 SARS epidemic [1]. The World Health Organization (WHO) declared the outbreak to be a Public Health Emergency of International Concern on January 30, 2020, and declared it to be a global pandemic on March 11, 2020 [2]. The virus has affected almost every country, every nation, and all races worldwide. The WHO has reported 269.2 million confirmed cases of COVID-19 and 5.30 million deaths internationally as of December 10, 2021 [3]. Although 8.42 billion vaccine doses were administered worldwide by December 10, only a little more than 64 million doses have been administered in low-income countries [3]. With the emergence of the Omicron variant, the disease is surging again in various parts of the world, thereby posing a challenge to vaccination measures [3]. At the time of this writing, the total number of COVID-19 infections in Pakistan is 1.28 million, with slightly less than 30,000 deaths [4]. Although the vaccination drive was initially slow in Pakistan, its pace is quickening. As of December 8, 2021, 130 million vaccine doses have been administered throughout Pakistan, whereas only 54 million people have been fully vaccinated, defined as having either completed the single-dose vaccine or both doses of the two-dose vaccine [4].

The clinical presentation of COVID-19 is variable [5]. It ranges from asymptomatic infection or mild upper respiratory symptoms in most cases to severe viral pneumonia with respiratory failure [6]. In most infected individuals, no symptoms or only minimal symptoms appear [7]. Symptomatic patients present with variable symptoms. The most common are fever, cough, generalized body aches, shortness of breath, anosmia, and loss of taste. The uncommon

symptoms are headache, nausea, and diarrhea [6]. Fever is the most prevalent reported symptom [8]. Continuous fever, shortness of breath, and presence of respiratory and gastrointestinal symptoms make a patient prone to develop severe disease. Moreover, the likelihood of intensive care unit (ICU) admission, mechanical ventilation (invasive and non-invasive), and death is high in such patients. In a study by Rongchen [9] et al., gastrointestinal symptoms were more strongly linked with worse outcomes. In Nigeria, Akin Abayomi [10] et al. found that cough, high-grade fever, and shortness of breath were the most common presenting symptoms. Symptom severity was the most important predictor of death. Among all other symptoms, shortness of breath had a worse prognostic value in terms of mortality. In contrast, isolated loss of the sense of smell and sense of taste was not linked with the development of critical disease and thus had good prognostic value.

Significant risk factors associated with worse outcomes are chronic illness, older age, and genetic predisposition [11]. In a study by Elizabeth [12] et al., older age was the most significant risk factor for death, followed by hematologic malignancies, immunosuppressive drugs, organ transplantation, uncontrolled diabetes mellitus, black race, and obesity. A study from Pakistan by Ambreen Chaudhry [13] et al. found that the risk factors responsible for worse outcomes, defined as ICU admission, invasive mechanical ventilation (IMV), and death, were older age and the presence of comorbidities.

Several studies have reported different mortality rates for patients admitted to different hospital departments, such as the ICU, high-dependency unit, and general ward. Mortality is highest for patients receiving IMV, followed by those managed with continuous positive airway pressure/non-invasive ventilation, high-flow nasal cannula, and oxygen administered via other

devices such as a simple face mask and nasal prongs [14]. The outcomes are good for patients who do not require supplemental oxygen and hospital admission [15].

The objective of the current study is to understand the demographic and clinical characteristics of patients with COVID-19 and the associated severity of illness and outcomes. We sought to perform an in-depth analysis of the various factors related to mortality, morbidity, and recovery from COVID-19. In Pakistan, data are very limited on the clinical and demographic characteristics of patients with COVID-19. Therefore, the results of this study will help us tailor our management and preparedness response to the COVID-19 pandemic.

This article was previously presented as an abstract at the 14th Biennial Chest Conference arranged by the Pakistan Chest Society at Karachi, Pakistan, on 4 December, 2021.

Material and Methods

This cross-sectional study was conducted from July 15, 2020, to July 3, 2021 in Peshawar, Khyber Pakhtunkhwa, Pakistan. All patients admitted to the study hospital were included in our study. Patients who were referred to another hospital or left without medical advice were excluded from our study. Informed written consent was obtained from all patients at admission to the hospital. The analysis was performed using SPSS, version 25 (IBM, Armonk, NY, USA) [16]

The association of various characteristics with mortality was analyzed. We used the post-stratification chi-square test and independent sample t-test to check the statistical significance of qualitative and quantitative characteristics, respectively. A value of $p \leq 0.05$ was considered statistically significant. To assess the adjusted association, we used multivariate logistic regression, with mortality as a dependent variable. These predictor variables were included in the final multivariate regression model, with a value of $p \leq 0.25$ on the univariate model as the dependent variable. In the final multivariate model, a value of $p \leq 0.05$ was considered significant. Time-to-event analysis was conducted to check for the difference in mortality across various groups.

Results

This study assessed a total of 1087 patients, of whom 449 (41%) were female and 731 (67%) were older than 50 years (Table 1). Most had a fever (96.4%), cough (95.3%), shortness of breath (72.7%), loss of taste (76.6%), and loss of smell (76.5%). Patients presented relatively less commonly with headache (28.1%), rhinorrhea (32.8%), nausea and vomiting (12.8%), and diarrhea (12.1%). Among comorbid conditions, hypertension (29.7%) and diabetes mellitus (24.4%) were more common compared with ischemic heart disease (9%) and end-stage renal disease (1.3%). The average length of hospital stay was 8.33 days. The overall mortality rate was 24.4% (268 patients) and was highest among those admitted directly to the ICU (49 of 56 patients, 88%) versus those admitted directly to the high-dependency unit (210 of 546 patients, 38%) and the general ward (9 of 485, 1.8%).

Table 1. Frequency of various characteristics of study participants (n = 1087).

Characteristics	No.	%	
Age			
	Below 50 years	356	33%
	Above 50 years	731	67%
Gender			
	Female	449	41%
	Male	638	59%
Fever			
	No	39	4%
	Yes	1048	96%
Cough			
	No	51	5%
	Yes	1036	95%
Headache			
	No	782	72%
	Yes	305	28%
Shortness of Breath			
	No	297	27%
	Yes	790	73%
Rhinorrhoea			

	No	730	67%
	Yes	357	33%
Loss of taste			
	No	254	23%
	Yes	833	77%
Diarrhea			
	No	955	88%
	Yes	132	12%
Nausea and Vomiting			
	No	948	87%
	Yes	139	13%
Loss of Smell			
	No	255	23%
	Yes	831	77%
Diabetes Mellitus			
	No	822	76%
	Yes	265	24%
Hypertension			
	No	764	70%
	Yes	323	30%
Ischemic Heart Disease			
	No	989	91%
	Yes	98	9%
End-Stage Renal Disease			
	No	1073	99%
	Yes	14	1%
Days of Hospitalization			
	mean (SD)	8.33 (7.94)	
Severity Level			
	Moderate	146	13%
	Severe	941	87%
Unit of Admission			
	HDU / Isolation ward	1031	95%
	ICU	56	5%
Mortality			
	Recovered	819	63%
	Died	268	24%

134

135 Simple stratification (Table 2) showed that mortality was significantly higher in patients older
136 than 50 years (37% vs. 11%) and in those with shortness of breath (41% vs. 2%), diarrhea (60%

vs. 24%), nausea and vomiting (60% vs. 23%), diabetes mellitus (62% vs. 16%), hypertension (53% vs. 18%), ischemic heart disease (74% vs. 24%), high level of disease severity (33% vs. 0%), and ICU admission (92% vs. 25%). Although mortality was also higher in female patients (31% vs. 27%) and in those with fever (29% vs. 16%), and end-stage renal disease (100% vs. 28%), the association was not statistically significant. Some characteristics showed a statistically significant protective effect from mortality, such as rhinorrhea (12% vs. 37%), loss of taste (2% vs. 100%), and loss of smell (2% vs. 100%). Length of stay was also significantly higher in patients who died compared with those who survived (11.43 vs. 7.63 days).

Table 2. Association of various characteristics with mortality.

Characteristics		Mortality				
		Died		Recovered		*p-value
		No.	%	No.	%	
Age						
	Below 50 years	35	11%	277	89%	< 0.001
	Above 50 years	233	37%	394	63%	
Gender						
	Female	118	31%	266	69%	0.217
	Male	150	27%	405	73%	
Fever						
	No	6	16%	31	84%	0.090
	Yes	262	29%	640	71%	

Cough						
	No	16	32%	34	68%	0.578
	Yes	252	28%	637	72%	
Headache						
	No	197	29%	480	71%	0.543
	Yes	71	27%	191	73%	
Shortness of Breath						
	No	5	2%	290	98%	< 0.001
	Yes	263	41%	381	59%	
Rhinorrhea						
	No	232	37%	394	63%	< 0.001
	Yes	36	12%	277	88%	
Loss of taste						
	No	254	100%	0	0%	< 0.001
	Yes	14	2%	671	98%	
Diarrhea						
	No	191	24%	620	76%	< 0.001
	Yes	77	60%	51	40%	
Nausea and Vomiting						
	No	186	23%	617	77%	< 0.001
	Yes	82	60%	54	40%	
Loss of Smell						

	No	255	100%	0	0%	< 0.001
	Yes	12	2%	671	98%	
Diabetes Mellitus						
	No	113	16%	577	84%	< 0.001
	Yes	155	62%	94	38%	
Hypertension						
	No	116	18%	535	82%	< 0.001
	Yes	152	53%	136	47%	
Ischemic Heart Disease						
	No	201	24%	647	76%	< 0.001
	Yes	67	74%	24	26%	
End-Stage Renal Disease						
	No	264	28%	671	72%	-
	Yes	4	100%	0	0%	
Days of Hospitalization						
	mean (SD)	11.43 (10.28)		7.63 (6.64)		< 0.001 ^a
Severity Level						
	Moderate	0	0%	136	100%	< 0.001
	Severe	268	33%	535	67%	
Unit of Admission at Arrival						
	HDU / isolation ward	219	25%	667	75%	< 0.001

	ICU	49	92%	4	8%	
--	-----	----	-----	---	----	--

* p-value represents results of chi-square test

^a p-value represents results of independent samples t-test

On multivariate regression (Table 3), several characteristics were statistically significant, as follows: shortness of breath (adjusted odds ratio [aOR] 31.3; 95% CI, 11.87–82.53; $p < 0.001$), ICU admission (aOR 28.3; 95% CI, 9.0–89.6; $p < 0.001$), diabetes mellitus (aOR 5.1; 95% CI, 3.2–8.2; $p < 0.001$), ischemic heart disease (aOR 3.4; 95% CI, 1.6–7; $p = 0.001$), nausea and vomiting (aOR 3.3; 95% CI, 1.7–6.6; $p = 0.001$) and prolonged hospital stay (aOR 1.04; 95% CI, 1.02–1.08; $p = 0.001$). These findings that the odds of shortness of breath was 31.3 times, ICU admission was 28.3 times, diabetes mellitus was 5.1 times, ischemic heart disease was 3.4 times, nausea and vomiting was 3.3 times, and prolonged hospital stay was four times higher in patients who died compared with those who survived. Patients with rhinorrhea were significantly protected on a multivariate model (aOR 0.3; 95% CI, 0.2–0.5; $p < 0.001$).

Table 3. Multivariate logistic regression analysis of various characteristics.

Characteristics		aOR ^a	95% CIs		p-value
			Lower	Upper	
Gender					
	Female	Ref			

	Male	0.725	0.483	1.086	0.119
*Fever					
	No	Ref			
	Yes	5.526	1.442	21.174	0.013
*Shortness of Breath					
	No	Ref			
	Yes	31.302	11.873	82.525	< 0.001
*Rhinorrhea					
	No	Ref			
	Yes	0.302	0.183	0.500	< 0.001
Diarrhea					
	No	Ref			
	Yes	1.262	0.633	2.515	0.509
*Nausea and Vomiting					
	No	Ref			
	Yes	3.347	1.688	6.639	0.001
*Diabetes Mellitus					
	No	Ref			
	Yes	5.079	3.153	8.179	< 0.001
Hypertension					
	No	Ref			
	Yes	1.546	0.963	2.481	0.071
*Ischemic Heart Disease					

	No	Ref			
	Yes	3.369	1.628	6.969	0.001
	*Days of Hospitalization	1.048	1.020	1.077	0.001
	*Unit of Admission				
	HDU / Isolation ward	Ref			
	ICU	28.330	8.955	89.631	< 0.001

163 * p-value represents results of chi-square test

164 ^a p-value represents results of independent samples t-test

165

166 The survival analysis comprised 1087 patients. Our analysis observed a cumulated total risk time
167 of 9184 days. The Kaplan–Meier survival plots for the sociodemographic and medical factors
168 that were statistically significant are presented in Figure 1. As can be inferred from the plots,
169 patients with fever (Fig 1A), shortness of breath (Fig 1B), ischemic heart disease (Fig 1C),
170 nausea and vomiting (Fig 1D), diabetes mellitus (Fig 1E), and ICU admission (Fig 1F) were
171 more likely to die compared with patients who did not have these signs and symptoms.

172 **Fig 1 Title: K-M Curves for various characteristics**

173 **Fig 1 Legend:** As shown, patients with fever (A), shortness of breath (B), ischemic heart disease
174 (C), nausea and vomiting (D), diarrhea (E), and ICU admission (F) were more likely to encounter
175 the worst outcome as compared with patients who did not have these characteristics.

Discussion

The severity of any given disease depends on the population's demographic and clinical characteristics [17]. Therefore, we aimed to study these factors to understand COVID-19 in detail. This study will help us improve the management steps to prevent severe disease outcomes. Clinicians and scientists are performing many kinds of studies to understand this novel disease, which has killed millions of people. Many studies have already been conducted, but with several drawbacks, such as a small sample size. Although this current investigation is a single-site study, the hospital is an ideal location to examine the COVID-19 cohort because it serves as a referral center for most of the province. This study included 1087 patients with COVID-19 from a single tertiary care institution. Our hospital had an overall mortality rate of 24%, which is comparable with that of most nearby tertiary care hospitals. In a multi-center study conducted by Zia Ul Haq [18] et al. in Peshawar, Pakistan, the inpatient mortality rate in a cohort of 179 patients was 29.1%.

The findings show that certain clinical and demographic factors may predispose patients to worse outcomes. Severe shortness of breath (OR 31) and admission to the ICU on presentation (OR 28), for example, were the strongest predictors of worse outcomes in our analysis, in favor of mortality. Direct admission to the ICU indicates that the patient's condition is rapidly deteriorating or that the patient arrived at the hospital very late and in critical condition. Furthermore, symptoms such as nausea and vomiting (OR 3.9), fever (OR 3.5), and diarrhea, (OR 1.52) predispose one to worse outcomes as well. In contrast, our study found that rhinorrhea indicated a higher likelihood of recovery, which has not been reported previously. In a survey by

Nausheen Nasir [19] et al. in Karachi, Pakistan, disease severity was associated with age older than 60 years (OR 1.92) and having shortness of breath (OR 4.43). In another study, Darbaz A [20] et al. in the United States found that patients presenting with gastrointestinal symptoms had higher hospitalization rates, ICU admission, and intubation. In contrast, Preethi Ramachandran [21] et al. compared the outcomes in two groups of patients with or without gastrointestinal symptoms and discovered that mortality did not differ between cases and controls (41.9% vs. 37.8%; $p = 0.68$). Secondary outcomes, such as length of stay (7.8 vs. 7.9 days; $p = 0.87$) and need for mechanical ventilation (29% vs. 26.9%; $p = 0.82$), also showed no statistically significant differences.

Many studies have found that the presence of comorbidities such as diabetes, hypertension, ischemic heart disease, and end-stage renal disease increases the severity of the disease [22, 23]. In our research, we came to a similar conclusion. According to the survival analysis in our study, patients with diabetes mellitus, hypertension, and ischemic heart disease had a lower chance of survival when admitted to the hospital with COVID-19 than patients without any of these comorbidities. Due to the small sample size, the findings could not be statistically tested because most patients who developed end-stage renal disease in our study were referred to other hospitals with dialysis services. Other authors have reported similar results. Naila Shoaib [24] et al. in Pakistan discovered a link between the severity of COVID-19 and the number and type of comorbidities. As the number of comorbidities increased, so did the disease severity. Patients who were older, had diabetes, or had high blood pressure were more likely to have a poor outcome.

Our study was conducted at a tertiary care hospital with a large sample size for one hospital. The study sample was diverse because the patients were referred from throughout the province to this tertiary care hospital. We evaluated both demographic and clinical characteristics to perform an in-depth analysis.

The limitations of this study are that we did not include patients from other hospitals for comparative analysis. Furthermore, we did not include the response to various treatments, and lastly, the patient's social characteristics, such as local residence, occupation, and income, were not included in this analysis.

Further research is needed to develop a comprehensive scoring system for COVID-19. The system for scoring should be practical and straightforward to predict the disease severity and the management steps for COVID-19. Both prospective and retrospective analyses from the global north and the global south are needed to identify the critical factors in managing this disease.

Conclusions

Our findings showed that older age, comorbidities, and direct admission to the ICU increase the risk of worse outcomes. Furthermore, shortness of breath, fever, and gastrointestinal symptoms also increase the risk of worse outcomes. In contrast, patients with isolated upper respiratory symptoms have a lower mortality rate. More research is needed to determine risk factors that increase the risk of disease severity and to devise a proper risk scoring system to initiate timely management.

239

240 Acknowledgments:

241 **Ethical Approval:** Ethical approval for the study was taken from Ethics Committee, Office of
242 Research Innovation & Commercialization (ORIC), Khyber Medical University, Peshawar,
243 bearing number DIR/KMU-EB/DO000667.

244 Informed written consent was taken from all the participants.







References:

1. Zheng J. SARS-CoV-2: An emerging coronavirus that causes a global threat. *Int J Biol Sci.* 2020;16(10): 1678-1685. doi: [10.7150/ijbs.45053](https://doi.org/10.7150/ijbs.45053).
2. Detail. Who.int. 2020 [cited Dec 13, 2021]. Available from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>.
3. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J. Coronavirus pandemic (COVID-19). Our World Data. 2020 [cited Dec 14, 2021]. Available from: <https://ourworldindata.org/covid-cases>.
4. National command operation center: national command operation center. 2021 [cited Dec 13, 2021]. Available from: <https://ncoc.gov.pk/covid-vaccination-en.php>.
5. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, et al. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien Klin Wochenschr.* 2021;133(7-8): 377-382. doi: [10.1007/s00508-020-01760-4](https://doi.org/10.1007/s00508-020-01760-4).
6. Vihta KD, Pouwels KB, Peto T, Pritchard E, Eyre DW, House T, et al. Symptoms and SARS-CoV-2 positivity in the general population in the UK. *Clin Infect Dis.* 2021. doi: [10.1093/cid/ciab945](https://doi.org/10.1093/cid/ciab945).
7. Alene M, Yismaw L, Assemie MA, Ketema DB, Mengist B, Kassie B, et al. Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis. *PLOS ONE.* 2021;16(3): e0249090. doi: [10.1371/journal.pone.0249090](https://doi.org/10.1371/journal.pone.0249090).

- 266 8. Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and
267 characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-
268 19): A systematic review and meta-analysis of 17515 patients. PLOS ONE. 2021;16(4):
269 e0249788. doi: [10.1371/journal.pone.0249788](https://doi.org/10.1371/journal.pone.0249788).
- 270 9. Chen R, Yu YL, Li W, Liu Y, Lu JX, Chen F, et al. Gastrointestinal symptoms associated
271 with unfavorable prognosis of COVID-19 patients: A retrospective study. Front Med (Lausanne).
272 2020;7: 608259. doi: [10.3389/fmed.2020.608259](https://doi.org/10.3389/fmed.2020.608259).
- 273 10. Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-
274 Peñacoba G, et al. Anosmia is associated with lower in-hospital mortality in COVID-19.
275 J Neurol Sci. 2020;419: 117163. doi: [10.1016/j.jns.2020.117163](https://doi.org/10.1016/j.jns.2020.117163).
- 276 11. Liu X, Yue X, Liu F, Wei L, Chu Y, Bao H, et al. Analysis of clinical features and early
277 warning signs in patients with severe COVID-19: A retrospective cohort study. PLOS ONE.
278 2020;15(6): e0235459. doi: [10.1371/journal.pone.0235459](https://doi.org/10.1371/journal.pone.0235459).
- 279 12. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
280 associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821): 430-
281 436. doi: [10.1038/s41586-020-2521-4](https://doi.org/10.1038/s41586-020-2521-4).
- 282 13. Chaudhry A, Ikram A, Baig MA, Salman M, Ghafoor T, Zakir H, et al. Mortality analysis
283 of COVID-19 confirmed cases in Pakistan. medRxiv [preprint]. 2020 Jan 1. doi:
284 [10.1101/2020.06.07.20121939](https://doi.org/10.1101/2020.06.07.20121939).
- 285 14. Rahim F, Amin S, Noor M, Bahadur S, Gul H, Mahmood A, et al. Mortality of patients
286 with severe COVID-19 in the Intensive Care Unit: An observational study from a major COVID-
287 19 receiving hospital. Cureus. 2020;12(10): e10906. doi: [10.7759/cureus.10906](https://doi.org/10.7759/cureus.10906).

- 288 15. Banerjee J, Canamar CP, Voyageur C, Tangpraphaphorn S, Lemus A, Coffey C, et al.
289 Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute
290 Care Setting With Supplemental Oxygen. JAMA Netw Open. 2021;4(4):e213990. doi:
291 10.1001/jamanetworkopen.2021.3990.
- 292 16. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors
293 for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.
294 PLOS ONE. 2021;16(3): e0247461. doi: [10.1371/journal.pone.0247461](https://doi.org/10.1371/journal.pone.0247461).
- 295 17. Az A, Sogut O, Akdemir T, Ergenc H, Dogan Y, Cakirca M. Impacts of demographic and
296 clinical characteristics on disease severity and mortality in patients with confirmed COVID-19.
297 Int J Gen Med. 2021;14: 2989-3000. doi: [10.2147/IJGM.S317350](https://doi.org/10.2147/IJGM.S317350).
- 298 18. UIHaq Z, Shahzad M, Khattak MI, Fazid S, Ullah N, Shireen A, et al. Clinical
299 Characteristics, Mortality and Associated risk factors in COVID-19 patients reported in ten
300 major hospitals of Khyber Pakhtunkhwa, Pakistan. J Ayub Med Coll Abbottabad JAMC.
301 2020;32 [Suppl: 1] (4): S633-S639.
- 302 19. Nasir N, Habib K, Khanum I, Khan N, Muhammad ZA, Mahmood SF. Predictors of
303 severity and mortality of COVID-19 at a tertiary care center in a Lower-middle income country.
304 Authorea Preprints. 2020 Oct 1.
- 305 20. Adnan D, Deshmukh AA, Khan SR, Rempert T, Dhana K, Mahdavinia M, et al.. S1358
306 gastrointestinal symptoms predict the outcomes of COVID-19 infection. Am J Gastroenterol.
307 2020;115(1): S685-S686. doi: [10.14309/01.ajg.0000707480.23480.66](https://doi.org/10.14309/01.ajg.0000707480.23480.66).

- 308 21. Ramachandran P, Onukogu I, Ghanta S, Gajendran M, Perisetti A, Goyal H, et al.
309 Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients. Dig
310 Dis. 2020;38(5): 373-379.
- 311 22. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity
312 and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8): 1069-1076. doi:
313 [10.1007/s42399-020-00363-4](https://doi.org/10.1007/s42399-020-00363-4).
- 314 23. Ali I. Syndemics at play: Chronic kidney disease, diabetes and COVID-19 in Pakistan.
315 Ann Med. 2021;53(1): 581-586. doi: [10.1080/07853890.2021.1910335](https://doi.org/10.1080/07853890.2021.1910335).
- 316 24. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity:
317 Studying the clinical and demographic risk factors for adverse outcomes. PLOS ONE.
318 2021;16(8): e0255999. doi: [10.1371/journal.pone.0255999](https://doi.org/10.1371/journal.pone.0255999).



Figure